Connect with us
This past year was not a good one for the Spanish pharmaceutical sector. According to a calculation, the six listed companies on the continuous market has...
Pharma Mar's investment in research and development (R&D) rose by 19.6% to $17.7 million (€14.7 million). Other operating expenses fell by 13% to $15.5 million (€12.9...
Sylentis is preparing for a new trial. The study has been approved by the FDA in 30 days and will be part of the marketing authorization...